RDNA-07. IDH1-MUTANT GLIOBLASTOMA (GBM) CELLS FROM A PATIENT POST-TUMOR TREATING FIELDS (TTFIELDS) THERAPY ARE SENSITIVE TO TTFIELDS IN VITRO

BACKGROUND: Tumor treating fields (TTFields) are FDA-approved for treatment of newly-diagnosed and recurrent GBM. TTFields extend progression-free survival and overall survival. Despite this advancement in patient outcome, many patients undergoing TTFields treatment ultimately progress with tumor re...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Michelhaugh, Sharon, Kiousis, Sam, Klinger, Neil, Mittal, Sandeep
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2018
Aiheet:
Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217513/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.923
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia